HLX07 + HLX10 + carboplatin + etoposide

HLX07 + HLX10 + carboplatin + etoposide is an investigational combination regimen for cancer treatment comprising two monoclonal antibodies and two chemotherapeutic agents. HLX07 is a recombinant humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody, categorized as a biobetter of cetuximab, developed by Shanghai Henlius Biotech. HLX10 is a recombinant humanized anti-programmed cell death protein 1 (PD-1) monoclonal antibody, also developed by Henlius, which acts as an immune checkpoint inhibitor, enhancing T-cell antitumor activity by blocking the PD-1 pathway. This regimen is combined with carboplatin (a platinum-based DNA cross-linking agent) and etoposide (a topoisomerase II inhibitor), both standard chemotherapeutic agents used in various cancers. The regimen is being studied for solid tumors, with a primary focus on extensive-stage small cell lung cancer and head and neck squamous cell carcinoma. HLX07 targets EGFR to inhibit tumor cell proliferation and survival, while HLX10 releases immune suppression mediated by PD-1. This combination aims to synergistically enhance antitumor efficacy by integrating immunotherapy with cytotoxic chemotherapy[1][4][5][6].

Other names

HLX07 + HLX10 + carboplatin + etoposide